Vericel Corporation $VCEL Stock Holdings Increased by Wellington Management Group LLP

Key Points

• Wellington Management Group LLP has increased its holdings in Vericel Corporation by 5.8%, acquiring an additional 74,723 shares to total 1,363,644 shares valued at approximately $60.85 million.
• Despite mixed ratings from analysts, Vericel currently holds an average rating of "Buy" with a consensus target price of $60.33.
• Vericel reported a revenue of $63.24 million for the quarter, showing a 20.1% increase year-over-year, and beat consensus EPS estimates with a loss of only $0.01 compared to expectations of a loss of $0.04.

Wellington Management Group LLP raised its position in shares of Vericel Corporation (NASDAQ:VCEL - Free Report) by 5.8% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,363,644 shares of the biotechnology company's stock after buying an additional 74,723 shares during the quarter. Wellington Management Group LLP owned about 2.72% of Vericel worth $60,846,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently modified their holdings of VCEL. Captrust Financial Advisors raised its holdings in Vericel by 3.4% in the 4th quarter. Captrust Financial Advisors now owns 6,111 shares of the biotechnology company's stock worth $336,000 after purchasing an additional 199 shares during the period. Portside Wealth Group LLC increased its holdings in shares of Vericel by 9.9% in the first quarter. Portside Wealth Group LLC now owns 6,546 shares of the biotechnology company's stock worth $292,000 after purchasing an additional 591 shares during the last quarter. Mariner LLC boosted its position in shares of Vericel by 7.7% during the 4th quarter. Mariner LLC now owns 9,209 shares of the biotechnology company's stock valued at $506,000 after acquiring an additional 659 shares during the last quarter. US Bancorp DE raised its position in shares of Vericel by 29.9% during the 1st quarter. US Bancorp DE now owns 3,071 shares of the biotechnology company's stock valued at $137,000 after buying an additional 706 shares in the last quarter. Finally, GAMMA Investing LLC boosted its holdings in shares of Vericel by 34.8% in the 1st quarter. GAMMA Investing LLC now owns 2,895 shares of the biotechnology company's stock worth $129,000 after purchasing an additional 748 shares during the period.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Stephens reaffirmed an "overweight" rating and set a $67.00 target price on shares of Vericel in a research report on Monday, June 16th. Wall Street Zen lowered Vericel from a "hold" rating to a "sell" rating in a research note on Monday, May 12th. Finally, Canaccord Genuity Group reduced their price target on Vericel from $61.00 to $58.00 and set a "buy" rating for the company in a research report on Friday, August 1st. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat, Vericel currently has an average rating of "Buy" and an average target price of $60.33.

Vericel Stock Down 3.3%

Shares of NASDAQ VCEL traded down $1.24 during mid-day trading on Monday, hitting $35.79. 369,153 shares of the company were exchanged, compared to its average volume of 625,231. The stock has a 50 day simple moving average of $38.84 and a 200-day simple moving average of $42.85. Vericel Corporation has a 1-year low of $33.09 and a 1-year high of $63.00. The firm has a market cap of $1.81 billion, a price-to-earnings ratio of 298.27 and a beta of 1.27.

Vericel (NASDAQ:VCEL - Get Free Report) last announced its earnings results on Thursday, July 31st. The biotechnology company reported ($0.01) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.04) by $0.03. Vericel had a net margin of 2.85% and a return on equity of 2.47%. The company had revenue of $63.24 million during the quarter, compared to analysts' expectations of $64.61 million. During the same quarter in the previous year, the business posted ($0.10) earnings per share. The firm's quarterly revenue was up 20.1% compared to the same quarter last year. Analysts anticipate that Vericel Corporation will post 0.14 earnings per share for the current fiscal year.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.